Comparative Pharmacology
Head-to-head clinical analysis: ANDRODERM versus TESTOSTERONE PROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDRODERM versus TESTOSTERONE PROPIONATE.
ANDRODERM vs TESTOSTERONE PROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.
Testosterone propionate is a short-acting androgen receptor agonist. It binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.
50-400 mg intramuscularly every 2-4 weeks. For androgen replacement, 50-100 mg IM every 2 weeks.
None Documented
None Documented
Clinical Note
moderateTestosterone propionate + Tranylcypromine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Tranylcypromine."
Clinical Note
moderateTestosterone propionate + Procarbazine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Procarbazine."
Clinical Note
moderateTestosterone propionate + Pirlindole
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Pirlindole."
Clinical Note
moderateTerminal elimination half-life is approximately 10–100 minutes (rapid), but due to transdermal absorption, effective half-life is extended to about 8–10 hours after patch application.
Terminal half-life: 0.8–1.2 hours (rapid elimination due to short ester chain; requires frequent dosing).
Approximately 90% of testosterone metabolites are excreted in urine as glucuronide and sulfate conjugates; 6% are excreted in feces via bile.
Renal: 90% (as glucuronide and sulfate conjugates); Fecal/Biliary: 10%.
Category C
Category D/X
Androgen
Androgen
Testosterone propionate + Moclobemide
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Moclobemide."